ArticleJournal of Alzheimer's disease reports
Caregiver burden, not patient cognitive impairment, predicts adherence to donepezil transdermal patch in Alzheimer's disease: A retrospective real-world study.
Article in Journal of Alzheimer's disease reports. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The donepezil transdermal patch is a useful option for Alzheimer's disease (AD) patients with poor oral adherence. However, treatment discontinuation due to skin irritation or management difficulties remains a clinical challenge. Objective: To identify predictive factors for the successful continuation of the donepezil transdermal patch in a real-world setting. Methods: A retrospective review included 26 AD patients newly prescribed or switched to the donepezil patch at a dementia center. Patients were divided into continuation (n = 15) and discontinuation (n = 11) groups based on a 12-week cutoff. We evaluated baseline demographics, Mini-Mental State Examination (MMSE), Clinical Dementia Rating-Sum of Boxes (CDR-SB), Alzheimer's Disease Assessment Scale-Cognitive Subscale for Activities of Daily Living (ADL-Cog), and caregiver burden using the 8-item Zarit Burden Interview (Zarit-8). Multivariate logistic regression identified risk factors for discontinuation. Results: Univariate analysis showed no significant differences between groups in age (p = 0.855), MMSE (p = 0.677), CDR-SB (p = 0.762), and ADL-Cog (p = 0.826). Although the mean Zarit-8 score was higher in the discontinuation group (14.00 ± 10.70 versus 7.86 ± 5.55, p = 0.171), this lacked statistical significance. However, multivariate regression revealed a higher Zarit-8 score was a significant independent predictor of discontinuation after adjusting for age (p = 0.038, OR = 1.134). Conclusions: Caregiver burden, rather than patient cognitive function or impairment in activities of daily living, significantly predicts discontinuation of the transdermal patch. To the best of our knowledge, no previous studies have utilized the Zarit burden scale as a clinical predictor of pharmacological adherence. Assessing caregiver reserve before introduction is crucial for maintaining adherence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.